Drug Trial Radar · NCT06383871
A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
Last checked: Nov 20, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
233
Planned (sponsor's estimate)
Start
Jun 6, 2024
Primary completion
Jun 2026
Study completion Jun 2026
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-7058.
Conditions
- Advanced Malignant Tumour
Interventions
HRS-7058 capsule/ HRS-7058 tabletDrug
HRS-7058 capsule/ HRS-7058 tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
- maximum tolerated dose (MTD)Time frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
- Phase II recommended dose (RP2D)Time frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
- Safety endpoints: adverse events (AE)Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 21 months]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.